Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|December 14, 2011
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fracturesP Hadji, J R Zanchetta, L Russo, et al.
Oncogene|August 11, 2015
Wnt addiction of genetically defined cancers reversed by PORCN inhibitionB Madan, Z Ke, N Harmston, et al.
The Journal of Clinical Investigation|December 10, 1999
Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injuryF Amersi, R Buelow, H Kato, et al.
Environmental Science & Technology|December 24, 2011
Implications of fecal bacteria input from latrine-polluted ponds for wells in sandy aquifersPeter S K Knappett, Larry D McKay, Alice Layton, et al.
JCI Insight|March 17, 2021
Gut-derived acetate promotes B10 cells with antiinflammatory effectsC I Daïen, J Tan, R Audo, et al.
Nature Communications|September 21, 2022
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degenerationYing Jiang, John J Alam, Stephen N Gomperts, et al.
Annals of Neurology|February 5, 1998
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupJ H Simon, L D Jacobs, M Campion, et al.
Neurology|August 1, 1997
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, D E Goodkin, L D Jacobs, et al.
Annals of Neurology|March 1, 1996
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Pageof 22